DR SHERINE M DSOUZA

DR.AKHILA S, DR.BHAVANA VASUDEV

Abstract

Novel biologicals for immunotherapy has marked impact on patients with cancer patient survival.However, ocular side of biological agents effects are uncommon and accounts for about 1%.We would like to report one such case who presented to us following administration of ipilimumab a newer biological agent which is a monoclonal antibody that activates immune system. A 62yr,a known diabetic and hypertensive with renal carcinoma with metastasis is on ipilimumab 4 cycles presented with loss of vision in left eye.BCVA of 6/6,N6 and 6/9P,N8 in Right eye and left eye respectively.Bilateral glaucomatous disc,LE features suggestive central retinal vein occulsion and inferior branch retinal artery occlusion showing multiple roth spots.This case would be presented with appropriate investigations and retinal images.